Alabama
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Alaska
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Arizona
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Arkansas
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
California
Duarte; City of Hope
Tandem High-Dose Therapy with Melphalan and Total Marrow Irradiation (TMI) with Peripheral Blood Progenitor Cell Support and Dexamethasone and Thalidomide Maintenance in Multiple Myeloma: A Phase I/II Trial
Duarte; City of Hope
Phase I/II Study of VELCADE (Bortezomib), Dexamethasone, and Revlimid (Lenalidomide) (VDR) versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid (VDCR) in Subjects with Previously Untreated Multiple Myeloma
Duarte; City of Hope![[*]](../images/newtiny.gif)
Correlating Organ Dose and Dose-Volume with Toxicities After Total Marrow Irradiation (TMI) Using Helical Tomotherapy in Patients with Multiple Myeloma Undergoing Hematopoetic Cell Transplantation (HCT)
Duarte; City of Hope
CALGB 100104/ECOG 100104: A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 (NSC #703813, IND #70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma
Duarte; City of Hope
A Phase 1 Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multipe Myeloma
Duarte; City of Hope
Multiple Myeloma Research Consortium Inc. Ancillary Tissue Collection Study
Duarte; City of Hope
A Phase II Multicenter Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Subjects with Relapsed or Refractory Multiple Myeloma
La Jolla; Scripps Clinic Medical Group
A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Colorado
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Connecticut
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Delaware
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Florida
Lecanto; Cancer and Blood Disease Center
A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Georgia
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Various Cities; Research Center
Multiple Myeloma Study CLBH589B2206
Hawaii
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Idaho
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Illinois
Chicago; University of Chicago
A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Indiana
Beech Grove; St. Francis Hospital and Health Centers
Safety, Efficacy, Dose-Finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Iowa
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Kansas
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Kentucky
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Louisiana
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Maine
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Maryland
Bethesda; Center for Cancer and Blood Disorders
A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Massachusetts
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Michigan
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Minnesota
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Mississippi
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Missouri
Jefferson City; Capitol Comprehensive Cancer Care Clinic
A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Montana
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Nebraska
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Nevada
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
New Hampshire
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
New Jersey
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Various Cities; Research Center
Multiple Myeloma Study CLBH589B2207
New Mexico
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
New York
Buffalo; Roswell Park Cancer Institute
A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.
Lake Success; Biomedical Research Alliance of New York
Relapsed or Refractory Multiple Myeloma - Adults
New York; Columbia University Medical Center
Myeloma Specimen Repository Protocol, Ancillary.
New York; Columbia University Medical Center
Double-Blinded Placebo Controlled Phase III Trial Comparing Dexamethasone (DEX) to the Combination of DEX + CC-5013 in Patients with Newly Diagnosed Multiple Myeloma.
New York; Columbia University Medical Center
Phase I/II Study of Liposomal Doxorubicin (Doxil®)/ Melphalan/ Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma
New York; Columbia-Presbyterian Medical Center
Study of the use of peripheral blood stem cells for allogeneic transplantation (PBSCT) in patients with advanced hematological malignancies at increased risk of relapse or transplant-related mortality
New York; Columbia-Presbyterian Medical Center
Study of donor leukocyte infusions in patients with recurrent or persistent hematological malignancies after allogeneic bone marrow transplantation.
New York; Columbia-Presbyterian Medical Center
Study of standard chemotherapy and radiotherapy before allogeneic stem cell transplantation
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Various Cities; Research Center
Multiple Myeloma Study CLBH589B2206
North Carolina
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
North Dakota
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Ohio
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Oklahoma
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Oregon
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Pennsylvania
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Rhode Island
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
South Carolina
Charleston; Charleston Hematology Oncology
A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
South Dakota
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Tennessee
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Texas
Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplatons A10 And AS2-1 In Patients With Multiple Myeloma
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Utah
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Vermont
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Virginia
Charlottesville; University of Virginia
Division of Hematology/Oncology seeks adults over the age of 18 with first relapse of Multiple Myeloma.
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Washington
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
West Virginia
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Wisconsin
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Wyoming
Various Cities; Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
International
Salzburg, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma
Wien, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma
Calgary, Alberta, Canada; Tom Baker Cancer Center
A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.
Edmonton, Alberta, Canada; Cross Cancer Institute
A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.
Aschaffenburg, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Augsburg, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Berlin, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Bremen, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Duisburg, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Essen, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Esslingen, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Frankfurt Am Main, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Göttingen, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Güstrow, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Gütersloh, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Hamburg, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Hamm, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Hannover, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Herne, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Jena, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Karlsruhe, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Kassel, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Koblenz, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Köln, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Leer, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Leipzig, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Ludwigshafen, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Magdeburg, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Minden, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
München, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Münster, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Neumünster, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Offenbach, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Offenburg, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Oldenburg, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Stuttgart, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Weiden, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Wiesbaden, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Würzburg, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
Zwickau, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma
